NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+3 more ↓
60%
Finnrick rating
#440 of 500 ranked vendors
87 of 125 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Mai Peptide's purity-focus record is broad and recent, with Retatrutide, GHK-Cu and Ipamorelin carrying the strongest repeat evidence despite some fill volatility and missing batch IDs. Weaker lines are dispersed but material: Tirzepatide has recent identity/purity misses, TB-500 and Semaglutide show identity failures, and BPC-157 remains volatile.

methodology →
vendor intelligence report
Vendor Intelligence Report: Mai Peptide

Corporate and domain records point past the storefront to a Xi'an/Shaanxi sales trail, HK-numbered contacts and unresolved UBO. The report maps Carrd COAs, crypto/off-platform payment rails, lookalike domains and parasite-review promotion.

37 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.77
84%
40
2
GHK-Cu
$0.06
83%
16
3
Ipamorelin
$0.90
76%
8
4
Tirzepatide
$0.30
63%
29
5
Tesamorelin
$2.20
59%
7
6
Cagrilintide
$2.40
56%
5
8
BPC-157
$0.70
48%
7
9
CJC-1295
$1.50
37%
3
10
TB-500
$1.20
35%
4
11
NAD+
$0.02
28%
3
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%1 Jul 2026: 59%1 Jul 2026: 59%1 Jul 2026: 59%1 Jul 2026: 59%1 Jul 2026: 60%10 Jul 2026: 60%13 Jul 2026: 60%13 Jul 2026: 60%13 Jul 2026: 60%30 Jul 2026: 61%30 Jul 2026: 60%30 Jul 2026: 60%30 Jul 2026: 60%21 Aug 2026: 59%25 Aug 2026: 59%25 Aug 2026: 59%27 Aug 2026: 59%4 Sep 2026: 59%7 Sep 2026: 59%15 Sep 2026: 59%16 Sep 2026: 59%18 Sep 2026: 59%18 Sep 2026: 59%18 Sep 2026: 60%18 Sep 2026: 60%18 Sep 2026: 60%18 Sep 2026: 60%19 Sep 2026: 60%19 Sep 2026: 60%24 Sep 2026: 61%24 Sep 2026: 60%24 Sep 2026: 60%25 Sep 2026: 60%29 Sep 2026: 60%1 Oct 2026: 60%6 Oct 2026: 61%29 Oct 2026: 60%29 Oct 2026: 61%29 Oct 2026: 61%2 Nov 2026: 61%17 Nov 2026: current 60%59%59%60%Jul 26Nov 26
Peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply
Mai Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
2 Nov 2026
Fail
TB-500
lab nameView COA
29 Oct 2026
Pass
GHK-Cu
lab nameView COA
29 Oct 2026
Pass
BPC-157
lab nameView COA
29 Oct 2026
Fail
Semaglutide
lab nameView COA
6 Oct 2026
Pass
Tirzepatide
lab nameView COA
1 Oct 2026
Pass
GHK-Cu
lab nameView COA
29 Sep 2026
Pass
GHK-Cu
lab nameView COA
25 Sep 2026
Fail
Tirzepatide
lab nameView COA
24 Sep 2026
Pass
Retatrutide
lab nameView COA
24 Sep 2026
Fail
Retatrutide
lab nameView COA
1-10 of 125

About Mai Peptide test results from Finnrick

Mai Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 125 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Mai Peptide peptides in this dataset are Semaglutide (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 125 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Mai Peptide? Mail in a sample (US only) and let us test it.

Test my supply